Abbott Labs (NYSE:ABT) is a diversified health care company that discovers, develops, manufacturers and markets a wide range of medical products and services. ABT will report first quarter earnings this week.

Recent Developments
ABT reported 4th quarter and full year earnings that beat consensus estimates. Although full year earnings were up 1% from the prior year, earnings came in at the high end of company guidance and ahead of the Street. Total sales were flat from 2005.

In the fourth quarter, sales were 2.8% year over year. There was a change in a Boehringer Ingelheim sales agreement which reduced year over year sales. Adjusting for this amended agreement, global sales increased over 14% year over year, driven by strong sales from the acquired Guidant business and Humira and International Nutritionals.

This strong display of sales came despite ABT's action to stop distributing Mobic, Flomax and Micardis for BI. These products represented over $2 billion in sales in 2005.

The company now earns a commission based on U.S. sales of the BI products. This move improved ABT's gross margin by over 500 basis points in 2006; however, the overall net impact was neutral to operating profit. SG&A and R&D costs rose dramatically as a result of the Guidant acquisition. Research and development costs increased to 9% of sales, up from 8.3%, but tax rates also fell to 22.8% from 30%.

Strong Business Segments
Worldwide vascular sales tripled primarily due to the addition of Guidant vascular business. The new launch of the Xact Carotid Stent System in Europe and parts of Asia also helped sales. Sales in nutritionals rose nearly 10% boosted by a near 20% rise in international sales. International demand for Ensure and infant formula is rising.

Pharma Still Weak, But Improvement Ahead
Worldwide pharma sales fell by nearly 10% in 2006; however, adjusting for the BI agreement, it would have risen by about 8%. International sales rose over 5%. Humira led sales growth with an increase of 36% in the U.S. market and 58% in international markets. Sales of the HIV drug Kaletra increased 11% to $1.1 billion -- sales in the United States rose 22% while international sales rose 7% (on constant currency basis). The sales of TriCor (cardiovascular) rose 18% gaining market share in the highly competitive U.S. cholesterol markets.

Some of ABT's products are under pressure from generic competition. For example, Synthroid sales declined 4% and are expected to exceed $400 million in sales in 2007. Ultane/Sevorane sales dropped 9% to $799 million, and sales for the Biaxin franchise fell 23% to $8 million worldwide.

Help from Acquisitions
In December ABT acquired Kos Pharmaceuticals for about $3.8 billion. Kos will bring a portfolio of respiratory and cardiovascular products, and will increase ABT's sales in cardiovascular to around $850 million. New drug-eluting stent products are expected to be launched in 2007. Other launches are expected for 2008 and 2009 as well.

'07 Expectations and Financial Valuations
Guidance from management expects earnings growth to be in the range of 9.5% to 12%, with an estimate of $2.77 to $2.83. Excluding recent acquisitions and divestitures, sales growth is expected to be 13 to 15%. ABT, however, is expected to face tough comparisons in the first half of 2007 as there will be some slight dilution from its recent acquisitions. Street consensus is smack in the middle of management guidance at 52 cents a share.

ABT's balance sheet is strong even after its recent spate of acquisitions. Cash on the balance sheet at year end was around $11.3 billion. Debt to total cap was about 33%. Return on equity however, is a bit weak at 12%. Several quarters of improving earnings and ABT's share buy back program of $2.5 billion should improve ROE. (To learn more, read Breaking Down The Balance Sheet.)

By most measures, ABT is not inexpensive. It has undergone significant restructuring and future, five-year earnings growth is expected to be around 11%. Abbott Labs also pays about a 2.4% dividend yield. The assimilation of its recent acquisitions should help accelerate earnings growth, and ABT seems poised to return to its historic consistent level of double digit growth as many S&P 500 companies begin to see their earnings slip.

Looking to cook up a market-stomping stock portfolio? Check out our FREE report "7 Ingredients to Market Beating Stocks" and get started right now!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!